DE4041688A1 - Therapeutisches mittel zur bekaempfung von viruserkrankungen - Google Patents
Therapeutisches mittel zur bekaempfung von viruserkrankungenInfo
- Publication number
- DE4041688A1 DE4041688A1 DE19904041688 DE4041688A DE4041688A1 DE 4041688 A1 DE4041688 A1 DE 4041688A1 DE 19904041688 DE19904041688 DE 19904041688 DE 4041688 A DE4041688 A DE 4041688A DE 4041688 A1 DE4041688 A1 DE 4041688A1
- Authority
- DE
- Germany
- Prior art keywords
- aromatic
- methanol
- fenalamide
- protons
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims description 14
- 229940124597 therapeutic agent Drugs 0.000 title claims description 14
- 241000700605 Viruses Species 0.000 title description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 58
- 230000003612 virological effect Effects 0.000 claims abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- RMQKPRRJSKFBRU-UHFFFAOYSA-N fenalamide Chemical compound CCN(CC)CCNC(=O)C(CC)(C(=O)OCC)C1=CC=CC=C1 RMQKPRRJSKFBRU-UHFFFAOYSA-N 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229950006906 fenalamide Drugs 0.000 claims description 19
- 150000002500 ions Chemical class 0.000 claims description 18
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 claims description 12
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 238000002451 electron ionisation mass spectrometry Methods 0.000 claims description 9
- 239000012050 conventional carrier Substances 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- CRPPMKFSMRODIQ-JDXPBYPHSA-N Hydroxy-gamma-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C=C\C(=O)NCC(C)(C)O CRPPMKFSMRODIQ-JDXPBYPHSA-N 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- YKCYCQSFKWWXPA-MKLZTHBUSA-N molport-000-824-482 Chemical compound C([C@]1(C)C2C(=O)C=C3[C@@]([C@@]2(CCC1C1(C)C)C)(C)CC[C@@]2(C)CC[C@](CC23)(C)C(=O)OC)C2=C1ON=C2 YKCYCQSFKWWXPA-MKLZTHBUSA-N 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 21
- 239000000126 substance Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 239000000287 crude extract Substances 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241001647011 Myxococcus stipitatus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OFVMLCJEDYAOIB-FYWRMAATSA-N 5-ethyl-2-methoxy-3-methyl-6-[2-[(e)-3-methyl-4-phenylbut-3-enyl]-1,3-oxazol-4-yl]pyran-4-one Chemical compound O1C(OC)=C(C)C(=O)C(CC)=C1C1=COC(CC\C(C)=C\C=2C=CC=CC=2)=N1 OFVMLCJEDYAOIB-FYWRMAATSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001600177 Cystobacterineae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000863421 Myxococcaceae Species 0.000 description 1
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OFVMLCJEDYAOIB-UHFFFAOYSA-N Phenoxan Natural products O1C(OC)=C(C)C(=O)C(CC)=C1C1=COC(CCC(C)=CC=2C=CC=CC=2)=N1 OFVMLCJEDYAOIB-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000009419 refurbishment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000007179 vy/2 agar Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904041688 DE4041688A1 (de) | 1990-12-24 | 1990-12-24 | Therapeutisches mittel zur bekaempfung von viruserkrankungen |
| PCT/EP1991/002503 WO1992011004A1 (de) | 1990-12-24 | 1991-12-23 | Fenalamiden als therapeutische mittel zur bekämpfung von viruserkrankungen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904041688 DE4041688A1 (de) | 1990-12-24 | 1990-12-24 | Therapeutisches mittel zur bekaempfung von viruserkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4041688A1 true DE4041688A1 (de) | 1992-07-09 |
| DE4041688C2 DE4041688C2 (enrdf_load_stackoverflow) | 1993-02-25 |
Family
ID=6421374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19904041688 Granted DE4041688A1 (de) | 1990-12-24 | 1990-12-24 | Therapeutisches mittel zur bekaempfung von viruserkrankungen |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE4041688A1 (enrdf_load_stackoverflow) |
| WO (1) | WO1992011004A1 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2968556B1 (fr) * | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
-
1990
- 1990-12-24 DE DE19904041688 patent/DE4041688A1/de active Granted
-
1991
- 1991-12-23 WO PCT/EP1991/002503 patent/WO1992011004A1/de active Application Filing
Non-Patent Citations (4)
| Title |
|---|
| DE-B.: M. Negwer Organisch-chemische Arzneimittel und ihre Synonyma, 5. Aufl., Bd. II, Akademie-Verlag, Berlin 1978, S. 751, Nr. 4113 * |
| HARADA, S. et.al.: Sensitive assay for neutralizating antibodies against AIDS-related viruses (HTLV-III/LAV). J. Immunol. Meth. 92, (1986), 177-181 * |
| POPOVIC, M. et.al.: Detection, isolation and production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224,(1984), 497-500 * |
| WENDLER, I. et.al.: Efficient replication of HTLV-III and STLV-IIImac in human Jurkat cells. Med. Microbiol. Immunol. 176, (1987), 273-280 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992011004A1 (de) | 1992-07-09 |
| DE4041688C2 (enrdf_load_stackoverflow) | 1993-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19638870A1 (de) | Verbindungen mit antimykotischer und cytostatischer Wirkung, Herstellungsverfahren, Mittel und DSM 11 092 | |
| CH649300A5 (de) | Ergopeptinderivate, ihre herstellung und verwendung. | |
| DE3741056A1 (de) | Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE3832362A1 (de) | Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung | |
| DE69818482T2 (de) | Physiologisch aktive substanzen tkr2449, verfahren zu ihrer herstellung und mikroorganismen | |
| DE4041688C2 (enrdf_load_stackoverflow) | ||
| DE60110908T2 (de) | Antibiotische tripropeptine und verfahren ihrer herstellung | |
| CH678855A5 (enrdf_load_stackoverflow) | ||
| EP0337152A1 (de) | Neue Furane und Lactone aus Streptomyceten, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE4041687C1 (enrdf_load_stackoverflow) | ||
| EP1532129B1 (de) | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen | |
| DE102004004901B4 (de) | Verfahren zur Herstellung von Sorbicillacton A | |
| DE3041130C2 (enrdf_load_stackoverflow) | ||
| CH640521A5 (en) | Cyclosporin D | |
| EP1049707B1 (de) | Ustilipide, verfahren zu deren herstellung sowie deren verwendung | |
| DE68906248T2 (de) | Antagonisten fuer den platelet-aktivierungsfaktor, phomactine genannt, ihre herstellung und verwendung. | |
| DE102004004906A1 (de) | O-Verbrückte Angucyclinone, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung | |
| WO1991000860A1 (de) | Stickstoffhaltige ambruticine, verfahren zu ihrer herstellung und ihre verwendung | |
| DE3935066A1 (de) | Verfahren zur isolierung von violacein und seine verwendung zur prophylaxe und therapie von viruserkrankungen | |
| WO1992011231A1 (de) | Phenylpolyenamide, herstellungsverfahren und mittel | |
| AT350716B (de) | Verfahren zur herstellung neuer antibiotika | |
| DE4041281C2 (de) | Therapeutische Mittel zur Bekämpfung von Viruserkrankungen | |
| DE19948644A1 (de) | Neue Peptaibole mit neuroleptischer Wirkung | |
| DE69904797T2 (de) | Antibakterielle Furopyridine | |
| DE2503893A1 (de) | Mikrobiologische produktion von biologisch aktiven 8,8'-bi-1h-naphtho- eckige klammer auf 2,3-c eckige klammer zu -pyranen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: DEUTSCHES PRIMATENZENTRUM GMBH, 3400 GOETTINGEN, D |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8330 | Complete disclaimer |